New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
INGELHEIM, Germany & RIDGEFIELD, Conn.--(BUSINESS WIRE)--Today, Boehringer Ingelheim announced Phase III data from the InPedILD trial, which assessed the pharmacokinetics (dosing) and safet......
